Medicus Pharma Ltd. (MDCX)

NCM – Real Time Price. Currency in USD

0.32

-0.02 (-5.26%)

At close: May 12, 2026, 4:00 PM EDT

0.31

-0.00 (-1.08%)

Pre-market: May 13, 2026, 8:40 AM EDT

06.05.2026

Medicus Pharma highlights positive dose-response in updated skin cancer trial results

Medicus Pharma (NASDAQ:MDCX) has reported additional results from a pre-specified expanded dataset analysis of its Phase 2 SKNJCT-003 trial, showing a positive dose-response relationship for its Doxorubicin Microneedle Array (D-MNA) in treating nodular basal cell carcinoma (BCC). The analysis builds on previously disclosed topline results and incorporates biological, histologic, and safety data from a refined group of 69 patients whose diagnoses met the study's intended inclusion criteria.

06.05.2026

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

PHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced results from a pre-specified expanded dataset analysis demonstrating positive dose response from its Phase 2 SKNJCT-003 study evaluating safety and efficacy of Doxorubicin Microneedle Array (D-MNA) to treat nodular basal cell carcinoma (BCC) of the skin, the most common type of skin cancer.

27.04.2026

Medicus Pharma lobbies Congress on SkinJect regulatory pathway for rare Gorlin syndrome

Medicus Pharma (NASDAQ:MDCX) said on Monday its chief executive and senior leadership team met with US lawmakers on Capitol Hill to seek support for regulatory and policy measures aimed at advancing its SkinJect therapy for patients with Gorlin syndrome, a rare inherited condition linked to recurrent skin cancers. The biotech company said the discussions focused on securing orphan drug designation for SkinJect for Gorlin syndrome, registrational investigational new drug approval for affected patients, and support for the rare disease pediatric FDA voucher program.

27.04.2026

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

Builds Support for Accelerated Access to SkinJect® for Gorlin Syndrome patients with a Rare Autosomal Dominant Disease Builds Support for Accelerated Access to SkinJect® for Gorlin Syndrome patients with a Rare Autosomal Dominant Disease

24.04.2026

Medicus Pharma advances Skinject in rare disease – ICYMI

Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress in advancing its Skinject program, highlighting a newly submitted orphan drug designation application with the US Food and Drug Administration targeting Gorlin syndrome, a rare genetic condition with no approved treatments. In an interview with Proactive, CEO Dr Raza Bokhari said the company is positioning 2026 as a “catalyst rich year,” driven by developments across its pipeline, led by Skinject.

17.04.2026

Medicus Pharma seeks orphan drug status for SkinJect in rare skin cancer disorder

Medicus Pharma (NASDAQ:MDCX) said on Friday it has submitted an application to the US Food and Drug Administration seeking orphan drug designation for its SkinJect therapy to treat basal cell carcinoma in patients with Gorlin Syndrome, a rare genetic condition marked by recurring skin cancers. The company said the filing expands its SkinJect program into an area of high unmet medical need, where treatment options are limited and often rely on repeated surgical procedures that can lead to cumulative physical and psychological burden.

17.04.2026

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Targets rare, high-burden genetic condition with no approved therapies; advances non-surgical treatment strategy for recurrent basal cell carcinoma Targets rare, high-burden genetic condition with no approved therapies; advances non-surgical treatment strategy for recurrent basal cell carcinoma

Videos

No Data

There is no data to display

Press releases

06.05.2026

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

27.04.2026

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

17.04.2026

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

06.04.2026

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention

Mechanism-Driven Study Design Focused on Capital Efficiency and Accelerated Development for Near-Term Value Creation, Addressing a $2 Billion Potential Target Market Mechanism-Driven Study Design Focused on Capital Efficiency and Accelerated Development for Near-Term Value Creation, Addressing a $2 Billion Potential Target Market

Medicus Pharma Ltd. (MDCX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Medicus Pharma Ltd. (MDCX)

Medicus Pharma highlights positive dose-response in updated skin cancer trial results

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

Medicus Pharma lobbies Congress on SkinJect regulatory pathway for rare Gorlin syndrome

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

Medicus Pharma advances Skinject in rare disease – ICYMI

Medicus Pharma seeks orphan drug status for SkinJect in rare skin cancer disorder

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Videos

No Data

Press releases

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention

Medicus Pharma highlights positive dose-response in updated skin cancer trial results

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

Medicus Pharma lobbies Congress on SkinJect regulatory pathway for rare Gorlin syndrome

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

Medicus Pharma advances Skinject in rare disease – ICYMI

Medicus Pharma seeks orphan drug status for SkinJect in rare skin cancer disorder

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Videos

No Data

Press releases

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention

Search stocks

Medicus Pharma Ltd. (MDCX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Medicus Pharma Ltd. (MDCX)

Medicus Pharma highlights positive dose-response in updated skin cancer trial results

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

Medicus Pharma lobbies Congress on SkinJect regulatory pathway for rare Gorlin syndrome

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

Medicus Pharma advances Skinject in rare disease – ICYMI

Medicus Pharma seeks orphan drug status for SkinJect in rare skin cancer disorder

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Videos

No Data

Press releases

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention

Medicus Pharma highlights positive dose-response in updated skin cancer trial results

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

Medicus Pharma lobbies Congress on SkinJect regulatory pathway for rare Gorlin syndrome

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

Medicus Pharma advances Skinject in rare disease – ICYMI

Medicus Pharma seeks orphan drug status for SkinJect in rare skin cancer disorder

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Videos

No Data

Press releases

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention